Ingo Hartung
@hartungingo.bsky.social
discovery chemistry nerd @Merckgroup; oncology, immunology, targeted protein degradation, ADCs; soccer, politics, tapas can slip into the feed; my own views
Pinned
Ingo Hartung
@hartungingo.bsky.social
· Feb 11
Talking about VHL-based #PROTACs: Check out our newest publication from the @proxidrugs.bsky.social consortium in which we propose & exemplify a generalizable workflow for the validation of E3 ligands for developing PROTACs.
pubs.acs.org/doi/10.1021/...
pubs.acs.org/doi/10.1021/...
Reposted by Ingo Hartung
📢We are delighted to share our latest themed collection on Induced-Proximity Pharmacology, guest edited by @lynjoneschembio.bsky.social, @hartungingo.bsky.social & Lindsey James!
Explore the articles that make up this fantastic collection, here👇
pubs.rsc.org/en/journals/...
#chemsky 🧪
Explore the articles that make up this fantastic collection, here👇
pubs.rsc.org/en/journals/...
#chemsky 🧪
July 2, 2025 at 9:31 AM
📢We are delighted to share our latest themed collection on Induced-Proximity Pharmacology, guest edited by @lynjoneschembio.bsky.social, @hartungingo.bsky.social & Lindsey James!
Explore the articles that make up this fantastic collection, here👇
pubs.rsc.org/en/journals/...
#chemsky 🧪
Explore the articles that make up this fantastic collection, here👇
pubs.rsc.org/en/journals/...
#chemsky 🧪
Great visit to our longstanding collaboration partners at the ICR discussing how small molecules continue to generate clinical impact. Learned a lot about how Zoran and his team tackle glue degrader discovery to deliver on the promise of expanding the druggable space.
Great day & night discussing how to design impactful drugs 💊 with @hartungingo.bsky.social!
Thanks for a great talk and lively discussion with @agako7.bsky.social, @robvanmontfort.bsky.social, Zoran Rankovich & the ICR Centre for Protein Degradation! Cheers 🍻!
Thanks for a great talk and lively discussion with @agako7.bsky.social, @robvanmontfort.bsky.social, Zoran Rankovich & the ICR Centre for Protein Degradation! Cheers 🍻!
July 1, 2025 at 5:48 AM
Great visit to our longstanding collaboration partners at the ICR discussing how small molecules continue to generate clinical impact. Learned a lot about how Zoran and his team tackle glue degrader discovery to deliver on the promise of expanding the druggable space.
Hi all, our old #sciencetwitter party place is reopening. Just in case you didn‘t get the invite… bring your Popcorn!
June 5, 2025 at 9:03 PM
Hi all, our old #sciencetwitter party place is reopening. Just in case you didn‘t get the invite… bring your Popcorn!
This paper sounds interesting. Oh wait… @proxidrugs.bsky.social
Heterobifunctional Protein Binders Enable Cell Type-Specific Killing Through In-cell Enrichment https://www.biorxiv.org/content/10.1101/2025.05.16.654562v1
May 19, 2025 at 5:55 PM
This paper sounds interesting. Oh wait… @proxidrugs.bsky.social
Guess who is sitting in front of me…
April 29, 2025 at 12:00 AM
Guess who is sitting in front of me…
Reposted by Ingo Hartung
🚀 An inspiring milestone worth sharing! 🎥
Yesterday marked the official kick-off event for the 2nd phase of our BMBF-funded #Cluster4Future @proxidrugs.bsky.social. Thanks to all scientists, stakeholders, citizens & schools for actively participating and making it a very special day for us!
Yesterday marked the official kick-off event for the 2nd phase of our BMBF-funded #Cluster4Future @proxidrugs.bsky.social. Thanks to all scientists, stakeholders, citizens & schools for actively participating and making it a very special day for us!
April 23, 2025 at 6:11 PM
🚀 An inspiring milestone worth sharing! 🎥
Yesterday marked the official kick-off event for the 2nd phase of our BMBF-funded #Cluster4Future @proxidrugs.bsky.social. Thanks to all scientists, stakeholders, citizens & schools for actively participating and making it a very special day for us!
Yesterday marked the official kick-off event for the 2nd phase of our BMBF-funded #Cluster4Future @proxidrugs.bsky.social. Thanks to all scientists, stakeholders, citizens & schools for actively participating and making it a very special day for us!
Reposted by Ingo Hartung
Una copa bien en alto por uno de mis autores favoritos. Gracias por las historias, las palabras, y la valentía. Buen viaje, Mario. 🥂📚
Farewell to the Last Writer of the Latin American Boom www.nytimes.com/2025/04/13/b...
Farewell to the Last Writer of the Latin American Boom www.nytimes.com/2025/04/13/b...
Mario Vargas Llosa: An Appreciation
The Peruvian author Mario Vargas Llosa was the world’s savviest and most accomplished political novelist.
www.nytimes.com
April 14, 2025 at 9:21 AM
Una copa bien en alto por uno de mis autores favoritos. Gracias por las historias, las palabras, y la valentía. Buen viaje, Mario. 🥂📚
Farewell to the Last Writer of the Latin American Boom www.nytimes.com/2025/04/13/b...
Farewell to the Last Writer of the Latin American Boom www.nytimes.com/2025/04/13/b...
Life could be worse… unfortunately, a pretty busy working week ahead.
April 6, 2025 at 10:51 AM
Life could be worse… unfortunately, a pretty busy working week ahead.
First impressions of comparing #AACR25 coverage on Bluesky with the other place. I am used to check the conference handle regularly to build my conference schedule. Some interesting findings on Twitter, nothing here yet. I hope conference coverage will pick up here as well.
April 6, 2025 at 10:27 AM
First impressions of comparing #AACR25 coverage on Bluesky with the other place. I am used to check the conference handle regularly to build my conference schedule. Some interesting findings on Twitter, nothing here yet. I hope conference coverage will pick up here as well.
Still difficult for me to judge the reach of this platform. #AACR25 (5 weeks from now) will be the 1st real test for science posting here. The meeting program is packed w/ sessions about novel ADC approaches, degraders/proximity inducers, targeting intracktables, overcoming resistance, using AI.
March 22, 2025 at 9:20 AM
Still difficult for me to judge the reach of this platform. #AACR25 (5 weeks from now) will be the 1st real test for science posting here. The meeting program is packed w/ sessions about novel ADC approaches, degraders/proximity inducers, targeting intracktables, overcoming resistance, using AI.
Reposted by Ingo Hartung
Besonders die Einleitung des Artikels ist wichtig. Ich frage mich die ganze Zeit: warum sollte Putin warten, bis Europa sich besser verteidigen kann? ME ist das einzige, was ihn noch aufhält, der ukrainische Widerstand.
March 22, 2025 at 8:33 AM
Besonders die Einleitung des Artikels ist wichtig. Ich frage mich die ganze Zeit: warum sollte Putin warten, bis Europa sich besser verteidigen kann? ME ist das einzige, was ihn noch aufhält, der ukrainische Widerstand.
A bit more than one month til #AACR25 and two months til the ASCMEDI-EFMC symposium - both in Chicago. I never thought that traveling to the US may ever become an issue for political reasons. Let‘s see what the next weeks will bring…
March 20, 2025 at 9:13 PM
A bit more than one month til #AACR25 and two months til the ASCMEDI-EFMC symposium - both in Chicago. I never thought that traveling to the US may ever become an issue for political reasons. Let‘s see what the next weeks will bring…
More about rewiring transcription with bifunctional TCIP molecules: biological proof-of-concept in sarcoma cell lines www.biorxiv.org/content/10.1...
March 19, 2025 at 7:06 AM
More about rewiring transcription with bifunctional TCIP molecules: biological proof-of-concept in sarcoma cell lines www.biorxiv.org/content/10.1...
A small molecule USP7 activator from the Buhrlage Group! Important information in the SI not to be missed: significant activity differences between enantiomers & an inactive control compound. A very strong data package further enabling studies of USP7 biology.
Small-molecule allosteric activator of ubiquitin-specific protease 7 (USP7) https://www.biorxiv.org/content/10.1101/2025.03.14.643379v1
March 17, 2025 at 6:36 AM
A small molecule USP7 activator from the Buhrlage Group! Important information in the SI not to be missed: significant activity differences between enantiomers & an inactive control compound. A very strong data package further enabling studies of USP7 biology.
Reposted by Ingo Hartung
📢Looking ahead to #AACR25 in Chicago — only 6 weeks away!
Join the Meet-the-Expert session with Prof. Paul Workman, where he’ll emphasize the critical role of high-quality chemical probes in drug discovery.
📅 April 29, 2025 | ⏰ 5:00-5:45 PM
Learn more👇
#CancerResearch
Join the Meet-the-Expert session with Prof. Paul Workman, where he’ll emphasize the critical role of high-quality chemical probes in drug discovery.
📅 April 29, 2025 | ⏰ 5:00-5:45 PM
Learn more👇
#CancerResearch
March 12, 2025 at 8:40 PM
📢Looking ahead to #AACR25 in Chicago — only 6 weeks away!
Join the Meet-the-Expert session with Prof. Paul Workman, where he’ll emphasize the critical role of high-quality chemical probes in drug discovery.
📅 April 29, 2025 | ⏰ 5:00-5:45 PM
Learn more👇
#CancerResearch
Join the Meet-the-Expert session with Prof. Paul Workman, where he’ll emphasize the critical role of high-quality chemical probes in drug discovery.
📅 April 29, 2025 | ⏰ 5:00-5:45 PM
Learn more👇
#CancerResearch
Summary: 1st Ph3 readout for a #PROTAC; likely path-to-approval in metastatic breast cancer patients w/ ESR1 mutations after having received endocrine therapy & CDK4/6 inhibitors; in line with previous clinical data; stock brokers don‘t understand Ph1/2 data. www.fiercebiotech.com/biotech/pfiz...
Pfizer, Arvinas post mixed breast cancer survival results in first phase 3 test for a PROTAC degrader
Pfizer and Arvinas’ estrogen receptor (ER) degrader has
www.fiercebiotech.com
March 12, 2025 at 6:44 AM
Summary: 1st Ph3 readout for a #PROTAC; likely path-to-approval in metastatic breast cancer patients w/ ESR1 mutations after having received endocrine therapy & CDK4/6 inhibitors; in line with previous clinical data; stock brokers don‘t understand Ph1/2 data. www.fiercebiotech.com/biotech/pfiz...
What a book! Very well deserved Booker Prize. Must-read recommendation. #ChemistsWhoRead
March 8, 2025 at 2:43 PM
What a book! Very well deserved Booker Prize. Must-read recommendation. #ChemistsWhoRead
Tja, das ist mal ein Romanbeginn, der meine Aufmerksamkeit schon im ersten Satz gewonnen hat…
March 1, 2025 at 4:00 PM
Tja, das ist mal ein Romanbeginn, der meine Aufmerksamkeit schon im ersten Satz gewonnen hat…
Small molecular weight drug molecules are products of design. Multiple characteristics are designed into one chemical structure. Read about how the combination of experimental data with calculated properties streamlines the discovery of oral designer PROTACs:
pubs.rsc.org/en/content/a...
@rsc.org
pubs.rsc.org/en/content/a...
@rsc.org
February 22, 2025 at 10:03 AM
Small molecular weight drug molecules are products of design. Multiple characteristics are designed into one chemical structure. Read about how the combination of experimental data with calculated properties streamlines the discovery of oral designer PROTACs:
pubs.rsc.org/en/content/a...
@rsc.org
pubs.rsc.org/en/content/a...
@rsc.org
Visiting #Irsee2025 was again a true pleasure. Not only the great science in a unique environment. But also the truly Bavarian weather, food & beer! Already looking forward to 25th til 27th February 2026 for #Irsee2026! @dechema.bsky.social
February 21, 2025 at 8:59 AM
Visiting #Irsee2025 was again a true pleasure. Not only the great science in a unique environment. But also the truly Bavarian weather, food & beer! Already looking forward to 25th til 27th February 2026 for #Irsee2026! @dechema.bsky.social
More biocatalysis at #Irsee2025. It took us a few years to bring Uwe Bornscheuer all the way from the baltic sea to south-western Bavaria. But it was worth the wait… reengineering methyl transferases and monooxygenases. @dechema.bsky.social
February 21, 2025 at 8:45 AM
More biocatalysis at #Irsee2025. It took us a few years to bring Uwe Bornscheuer all the way from the baltic sea to south-western Bavaria. But it was worth the wait… reengineering methyl transferases and monooxygenases. @dechema.bsky.social
Reposted by Ingo Hartung
The Hit to Lead process is an integral part of contemporary drug discovery.
A perspective just published in #ChemMedChem (@chemistryeurope.bsky.social), highlight the new set of @euromedchem.bsky.social best practices focused on H2L.
chemistry-europe.onlinelibrary.wiley.com/doi/10.1002/...
A perspective just published in #ChemMedChem (@chemistryeurope.bsky.social), highlight the new set of @euromedchem.bsky.social best practices focused on H2L.
chemistry-europe.onlinelibrary.wiley.com/doi/10.1002/...
The European Federation for Medicinal Chemistry and Chemical Biology (EFMC) Best Practice Initiative: Hit to Lead
Best practices for the Hit-to-Lead phase of drug discovery are exemplified in this article, with links to further materials and references as a learning resource. This consensus output was produced b....
chemistry-europe.onlinelibrary.wiley.com
February 21, 2025 at 8:07 AM
The Hit to Lead process is an integral part of contemporary drug discovery.
A perspective just published in #ChemMedChem (@chemistryeurope.bsky.social), highlight the new set of @euromedchem.bsky.social best practices focused on H2L.
chemistry-europe.onlinelibrary.wiley.com/doi/10.1002/...
A perspective just published in #ChemMedChem (@chemistryeurope.bsky.social), highlight the new set of @euromedchem.bsky.social best practices focused on H2L.
chemistry-europe.onlinelibrary.wiley.com/doi/10.1002/...
The new perspective from the @euromedchem.bsky.social Best Practice Initiative is now online: chemistry-europe.onlinelibrary.wiley.com/doi/abs/10.1... Best practice recommendations for the optimization from a Hit to a Lead. Kudos to Bob Young & Jean Quancard for driving this initiative!
February 21, 2025 at 7:55 AM
The new perspective from the @euromedchem.bsky.social Best Practice Initiative is now online: chemistry-europe.onlinelibrary.wiley.com/doi/abs/10.1... Best practice recommendations for the optimization from a Hit to a Lead. Kudos to Bob Young & Jean Quancard for driving this initiative!
The power & coolness of biocatalysis at #Irsee2025: Rebecca Buller from Zurich University of Applied Sciences about strategies to evolve designer enzymes. Enabling the chlorination of the complex macrolide soraphen and the derivatization of terpenes.
February 21, 2025 at 7:49 AM
The power & coolness of biocatalysis at #Irsee2025: Rebecca Buller from Zurich University of Applied Sciences about strategies to evolve designer enzymes. Enabling the chlorination of the complex macrolide soraphen and the derivatization of terpenes.